Feed aggregator

Aldeyra's Small Molecule Significantly Helps Allergy-Related Eye Symptoms

Biospace news - Tue, 04/27/2021 - 02:00
Top-line results from the Phase III INVIGORATE trial show Aldeyra Therapeutics’, reproxalap, significantly reduced ocular itching in patients with allergic conjunctivitis.

Young Adult COVID-19 Cases Boom as Older Generations Vaccinate

Biospace news - Tue, 04/27/2021 - 02:00
As vaccinations against COVID-19 continue across the U.S., there appears to be an increase in cases in younger populations.

Galectin Therapeutics Launches NASH Cirrhosis Info Site for Physicians and Patients

Biospace news - Tue, 04/27/2021 - 02:00
Galectin Therapeutics takes its role seriously, as perhaps the only company developing a therapy for non-alcoholic steatohepatitis (NASH) cirrhosis, an advanced form of NASH. Along with its Phase IIb/III clinical trial, it recently launched NAVIGATEnash.com.

2021 COVID-19 News: COVID-19 Possible Spread in Vehicles, US to Share AZ's COVID-19 Vaccine Globa...

Biospace news - Tue, 04/27/2021 - 02:00
Please check out the biopharma industry's COVID-19 stories that are trending for April 27, 2021.

How COVID-19 impacted UK healthcare

World Pharma News - Mon, 04/26/2021 - 12:00
Just one third of people in the UK managed to access the hospital care they needed at the peak of the first wave of the Covid-19 pandemic - according to new research from the University of East Anglia.

A new study published today looks at the extent to which people managed to access NHS healthcare in April 2020, and as lockdown restrictions eased.

Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands

World Pharma News - Mon, 04/26/2021 - 10:00
Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna's COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine supply needs.

Sanofi will leverage its established infrastructure and manufacturing expertise at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Moderna's COVID-19 vaccine, starting in September 2021.

FDA Officially Lifts Hold on UniQure’s Promising Hemophilia B Therapy

Biospace news - Mon, 04/26/2021 - 02:00
There is hope for uniQure’s HOPE-B trial after all. Shares of uniQure NV are climbing this morning after the company announced the clinical hold on its hemophilia B gene therapy has been lifted by the U.S. Food and Drug Administration.

Lack of Funding Drives Biotech to Suspend Drug-Resistant Antibiotic Pipeline

Biospace news - Mon, 04/26/2021 - 02:00
Five-year-old X-Biotix announced it is throwing in the towel on its antibacterial research efforts and changing gears for its corporate strategy.

Axsome Therapeutics AXS-05 Priority Review by FDA Could Speed Up Help for MDD Patients

Biospace news - Mon, 04/26/2021 - 02:00
In keeping with Axsome’s mission of providing a solution for central nervous system (CNS) disorders that are difficult to treat, AXS-05 was developed to help patients exhibiting treatment-resistant depression (TRD) and major depressive disorder (MDD).

Sanofi Partners With Moderna to Answer Global Demand for COVID-19 Vaccines

Biospace news - Mon, 04/26/2021 - 02:00
Sanofi will use its manufacturing capabilities to support the development of 200 million doses of the Moderna COVID-19 vaccine beginning in September.

Ocugen-Bharat Biotech Vaccine Shows Efficacy Against B.1.617 Variant

Biospace news - Mon, 04/26/2021 - 02:00
A new study published online has provided some hope for the citizens in India, with researchers suggesting that the Covaxin vaccine, developed by Bharat Biotech and Pennsylvania-based Ocugen, could neutralize the SARS-CoV-2 variant leading the second wave in the country.

AstraZeneca and Sanofi Announce Big Breakthrough With RSV Vaccine

Biospace news - Mon, 04/26/2021 - 02:00
AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term infants.

Clinical Catch-Up: April 19-23

Biospace news - Mon, 04/26/2021 - 02:00
It was a busy week for non-COVID-19-related clinical trial news, while fairly quiet on the COVID-19 arena. Here’s a look.

Death, Disability Among Side Effects of Chinese COVID-19 Vaccines, Leaked Documents Reveal

Biospace news - Mon, 04/26/2021 - 02:00
Leaked documents from provincial and municipal governments in China reveal a slew of previously unreported severe adverse events related to COVID-19 vaccines made and administered in China.

Biotech SPACs Can Expect a Good Runway as Investors Focus on Quality

Biospace news - Mon, 04/26/2021 - 02:00
Special Purpose Acquisition Companies (SPACs) are here to stay, offering one more way for companies to access public markets. But doing so isn’t a quick snap of the fingers.

Artificial intelligence model predicts which key of the immune system opens the locks of coronavirus

World Pharma News - Fri, 04/23/2021 - 12:00
The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them. The immune defense is able to recall the pathogens it has encountered previously, on which, for example, the effectiveness of vaccines is based.

FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review

World Pharma News - Fri, 04/23/2021 - 10:00
Following a thorough safety review, including two meetings of the CDC's Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

University of Oxford-Novavax Malaria Vaccine Demonstrates 77% Efficacy in Children

Biospace news - Fri, 04/23/2021 - 02:00
The same group at the University of Oxford and the Jenner Institute that developed the AstraZeneca-Oxford COVID-19 vaccine reported that their investigational malaria vaccine, R21/Matrix-M, demonstrated 77% efficacy in children over 12 months of follow-up.

CEO Salaries for the Top 20 Pharma Companies by Market Cap

Biospace news - Fri, 04/23/2021 - 02:00
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and Astra...

FDA Advisory Committee to Review Checkpoint Inhibitors Greenlit Under Accelerated Approval

Biospace news - Fri, 04/23/2021 - 02:00
The fate of three cancer immunotherapies that had been authorized under the U.S. Food and Drug Administration’s Accelerated Approval pathway will be determined next week following failures in confirmatory trials.